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Objective—The p75 neurotrophin receptor (p75NTR) contributes to diabetes mellitus−induced defective postischemic 
neovascularization. The interleukin-33 receptor ST2 is expressed as transmembrane (ST2L) and soluble (sST2) isoforms. 
Here, we studied the following: (1) the impact of p75NTR in the healing of ischemic and diabetic calf wounds; (2) the link 
between p75NTR and ST2; and (3) circulating sST2 levels in critical limb ischemia (CLI) patients.
Methods and Results—Diabetes mellitus was induced in p75NTR knockout (p75KO) mice and wild-type (WT) littermates by 
streptozotocin. Diabetic and nondiabetic p75KO and WT mice received left limb ischemia induction and a full-thickness 
wound on the ipsilateral calf. Diabetes mellitus impaired wound closure and angiogenesis and increased ST2 expression 
in WT, but not in p75KO wounds. In cultured endothelial cells, p75NTR promoted ST2 (both isoforms) expression through 
p38MAPK/activating transcription factor 2 pathway activation. Next, sST2 was measured in the serum of patients with 
CLI undergoing either revascularization or limb amputation and in the 2 nondiabetic groups (with CLI or nonischemic 
individuals). Serum sST2 increased in diabetic patients with CLI and was directly associated with higher mortality at 1 
year from revascularization.
Conclusion—p75NTR inhibits the healing of ischemic lower limb wounds in diabetes mellitus and promotes ST2 expression. 
Circulating sST2 predicts mortality in diabetic CLI patients. (Arterioscler Thromb Vasc Biol. 2012;32:00-00.)
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Soluble ST2 Is Regulated by p75 Neurotrophin Receptor  
and Predicts Mortality in Diabetic Patients With  
Critical Limb Ischemia
Andrea Caporali, Marco Meloni, Ashley M. Miller, Klemens Vierlinger, Alessandro Cardinali,  
Gaia Spinetti, Audrey Nailor, Ezio Faglia, Sergio Losa, Ambra Gotti, Orazio Fortunato,  
Tijana Mitic, Manuela Hofner, Christa Noehammer, Paolo Madeddu, Costanza Emanueli
Critical limb ischemia (CLI) is the end stage of lower extremity peripheral artery disease, in which severe 
obstruction of blood flow (BF) results in rest pain, ischemic 
ulcers, and a significant risk for limb loss. Diabetes melli-
tus (DM) heavily contributes to the prevalence and severity 
of ischemic disease, through acceleration of atherosclero-
sisand induction of microangiopathy.1 Moreover, DM com-
promises the native neovascularization response, which 
helps restoring tissue perfusion after an ischemic event.2,3 
The reasons for this angiogenic default in DM are not com-
pletely understood. Current revascularization treatments are 
expensive and mostly palliative, leaving the patient with 
sequelae and disabilities requiring additional intervention 
and hospitalization.4
The neurotrophin receptor p75 neurotrophin receptor 
(p75NTR) is a member of the tumor necrosis factor (TNF)-α 
receptors family. We previously demonstrated that p75NTR 
is implicated in DM-induced impairment of reparative 
neovascularization5. In fact, DM induces p75NTR expression 
in microvascular endothelial cells (ECs) of ischemic limb 
muscles and intra-scapular wounds.6,7 In turn, p75NTR reduces 
EC survival and functional capacities allowing for the angio-
genesis process.5 The expression and possible pathogenic role 
of p75NTR in ischemic lower limb ulcers associated or not with 
DM has never been studied.
The ST2 receptor (also known as interleukin 1 receptor-
like 1 [IL1RL1]) belongs to the Toll-like/IL-1–receptor 
superfamily.8 Soluble (sST2) and transmembrane (ST2L) 
isoforms are transcribed from a dual promoter system driving 
differential mRNA expression.9 IL-33 belongs to the IL-1 
cytokine superfamily and binds both ST2L and sST2. IL-33/
ST2L binding leads to activation of transcription factors such 
as nuclear factor κ-light-chain-enhancer of activated B cells 
and activator protein 1  via TNF receptor–associated factor-6, 
IRAK-1/4, and mitogen-activated protein kinases.10 By 
contrast, sST2 functions as a decoy receptor.11 Recent studies 
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suggest cardiovascular functions of the IL-33/ST2 system.12 
In particular, IL-33, via ST2L, prevents cardiomyocyte 
apoptosis and improves cardiac function and survival in mice 
after myocardial infarct (MI).13 Moreover, IL-33 promotes 
angiogenesis14 and prevents atherosclerosis development.15 
Cellular sources of sST2 in the cardiovascular system include 
ECs16,17 and cardiomyocytes.18 Importantly, sST2 was identified 
as a novel circulating biomarker of heart failure and MI.19,20 
Moreover, sST2 was proposed to predict mortality in a series 
of both cardiovascular and noncardiovascular pathological 
conditions in human patients, including acute MI21 and heart 
failure.22 However, to the best of our knowledge, the IL-33/
ST2 system was never investigated in the context of limb 
ischemia and DM ischemic complications.
Here, taking occasion of our recently established mouse 
model of ischemic lower limb wound healing23 and of mice 
with p75NTR gene knockout24 (p75KO), we have studied the 
impact of p75NTR in this experimental setting, associated or not 
with DM. We provide evidence that p75NTR deletion prevents 
features of delayed wound healing typical of DM, including 
impaired angiogenesis in the granulation tissue and increased 
EC apoptosis. Additionally, we have identified that p75NTR 
positively regulates ST2 expression in both skin wounds and 
cultured ECs and the molecular pathway that link p75NTR and 
ST2 in ECs. Moreover, we provide the first ever evidence that 
circulating sST2 is increased in patients with CLI and DM, 
where sST2 levels directly correlate with the severity of dis-
ease. Finally, we report that in patients with DM and CLI 
undergoing revascularization to attempt limb salvage, circu-
lating sST2 levels are directly associated with mortality within 
1 year of follow-up.
Materials and Methods
Detailed Materials and Methods and human patient characteristics 
are available in the online-only Data Supplement.
Human Samples
Our study was performed using blood samples of the follow-
ing: (1) nonischemic, nondiabetic subjects (n=11); (2) nondiabetic 
CLI patients undergoing revascularization (n=8); (3) diabetic CLI 
patients undergoing revascularization (n=53); and (4) diabetic CLI 
patients undergoing limb amputation (n=14). We additionally used 
samples from limb amputation for immunohistochemical analyses. 
Patient characteristics are reported in the Table. Clinical outcome 
at 1 year follow-up was available for the 53 diabetic CLI patients 
undergoing revascularization, and it is reported in Table I in the 
online-only Data Supplement. Human studies complied with the 
ethical principles stated in the Declaration of Helsinki and were 
covered by ethical approvals for sample and anonymized data col-
lection (IRCCS-Multimedica numbers 020/2008 and 011/2009) and 
for importing, storage, and analyses of samples at the University of 
Bristol (NHS-NRES 11SW/0093).
Animal Procedures
All procedures complied with the standards stated in the Guide for 
the Care and Use of Laboratory Animals (Institute of Laboratory 
Animal Resources, National Academy of Sciences, Washington, DC; 
1996) and were approved by the UK Home Office. WT littermates 
and 6- to 7-week-old male p75KO24 (genetic background, C57BL/6J) 
were made diabetic using streptozotocin25 or left normoglycemic 
after STZ buffer. At either 1 or 3 months of diabetes mellitus, left 
hindlimb ischemia was induced by femoral artery occlusion.26 At the 
same occasion, a full-thickness wound was created in the thigh dorsal 
skin of the ischemic legs using a sterile 5-mm-wide biopsy punch.23 
Laser Doppler was performed at baseline to confirm limb ischemia 
and at 3, 7, and 14 days thereafter to monitor BF recovery5,26 Wound 
closure was analyzed at the same time points.23
Table. Clinical Characteristic of Diabetic and Nondiabetic Patients
Patients
No Diabetic Patients,  
No Ischemic Patients  
Undergoing Vena Saphena  
Stripping as Cosmetic  
Procedure (n=11)
No Diabetic Patients  
With CLI Undergoing  
Revascularization (n=8)
Diabetics Patients  
With CLI Undergoing  
Revascularization (n=53)
Diabetic Patients  
With CLI Undergoing Limb  
Amputation (n=14)
Age, y 61.9±9.1 74.63±9.21 68.46±10.074 68.09±9.06
Sex 5/11 M 5/8 M 38/53 M 10/14 M
Diabetes mellitus 0 0 53/53 TD2 6/14 TD18/14 TD2
HbA1c, % Hb NR NR 7.76±1.97 8.08±1.63
Platelet, 103/mm 231±69.60 266.37±98.24 291.60±117.67 335.66±104.42
Insulin therapy 0/11 INS 0/8 INS 40/53INS 10/14 INS
Antiplateletdrugs 0 7/8 ASA 37/53 ASA7/53 CLO 2/14 ASA3/14 TICL3/14CLO
4/8 TICL 16/53 TICL 3/14 TICL
2/8 CLO 7/53 CLO 3/14CLO
1/8 AntiCOA 10/53 AntiCOA 0/14 AntiCOA
Antiglycemic drugs 0/11 AGD 0/8 AGD 11/53 AGD 0/14 AGD
Diet 0/11 DI 0/8 DI 2/53 DI 0/14 DI
Hypertension 0/11 HYP 4/8 HYP 35/53 HYP 5/14 HYP
Neuropathy NR NR 5/53 NEU 2/14 NEU
Retinopathy NR NR 9/53 RET 5/14 RET
CAD 0/11 CAD 3/8 CAD 28/53 CAD 8/14 CAD
TD1 indicates type 1 diabetes mellitus; TD2, type 2 diabetes mellitus; INS, insulin; AGD, antiglycemic drugs; DI, diet; HYP, hypertension; NEU, neuropathy; RET, 
retinopathy; CAD, coronary artery disease; NR, not recorded; ASA, acetylsalicylic acid; TICL, ticlopidine; CLO, clopidogrel; AntiCOA, dicumarolic anticoagulants.
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Immunhistochemistry on Murine 
and Human Tissues
Histology sections were prepared from mouse ischemic wounds and 
limb muscles (adductor and gastrocnemious) and from the skin of the 
amputated lower legs of diabetic CLI patients. In murine sections, 
capillary and arteriole densities were measured after staining with 
an antibody for α-smooth muscle actin and for either CD31 or fluo-
rescent isolectin-B4 (EC markers). EC apoptosis was assessed by in 
situ terminal deoxynucleotidyl transferase dUTP nick end labeling 
assay combined with CD31 staining. Mouse sections were addition-
ally stained with antibodies for ST2 and p75NTR. Human samples were 
stained for ST2 and IL-33.
RNA Extraction, Microarray, and 
Quantitative RT-PCR on Mouse Samples
RNA extractions and microarray methods are reported in supple-
ments (GEO accession number, GSE34675). Quantitative RT-PCR 
for sfrp1 (secreted frizzled-related protein 1), Hpx (hemopexin), 
clu (clusterin), tnc (tenascin), krt20 (keratin 20), vegfa (vascular 
endothelial growth factor A), vezf1 (vascular endothelial zinc fin-
ger 1), itgb1 (integrin β-1), birc5 (survivin), pttg1 (securin), and 
il-33 and for the housekeeping hprt1 (hypoxanthine phosphoribosyl-
transferase 1) and rpl13a (60S ribosomal protein L13a) or 18s (18s 
ribosomal RNA) was performed using validated primers (Applied 
Biosystems). Primers for murine il1rl1 (ST2) enabling to distin-
guish mRNA expression of sST2 and ST2L isoforms are reported 
in supplements.
Cells and Cell Culture
Human umbilical vein ECs (HUVECs, Lonza) were grown in EGM-2 
(EBM basal medium supplemented with growth factors; Lonza) with 
2% fetal bovine serum. When required, HUVECs were cultured in 
EBM overnight and then stimulated with TNF-α (10 ng/mL R&D 
Systems), phorbol-12-myristate-13-acetateate (1 μmol/L, Sigma), 
or vehicles for 16 hours. Small interfering RNA oligonucleotides for 
p75NTR, activating transcription factor 2 (ATF-2) and c-Jun (100 pmol, 
Dharmacon) or a scrambled oligonucleotide were transfected into 
HUVECs using Lipofectamine 2000 (Life Technology). Adenoviral 
vectors carrying human p75NTR or Null control are described in 
Caporali et al5 and were used as given in Caporali et al.5
Western Blot Analyses
Western blot analyses for p75NTR, ST2, IL-33, phospo (Thr180/
Tyr182), and total p38 mitogen-activated protein kinase (p38MAPK), 
phospho (Thr69/Thr71), and total ATF-2, phospho (Thr183/Tyr185) 
and total c-Jun N-terminal kinase (Cell Signaling), c-Jun and α/β-
tubulin, were performed in HUVECs as described.5
ELISA
Concentrations of sST2, VEGF-A, placental growth factor, soluble 
Tie-2 (sTie-2; angiopoietin-1 receptor), thrombospondin-1 (all from 
R&D Systems), TNF-α (eBiosciencies), and IL-33 (Prepotech) in 
HUVEC medium or human serum were quantified by commercial 
ELISA kits.
Statistical Analyses
Group differences of continuous variables were compared by 1-way 
ANOVA or Student t test, as appropriate. Continuous data are 
expressed as mean±SEM. A P value <0.05 was considered statisti-
cally significant. Determinants of the prognostic value of circulating 
sST2 levels were assessed using multivariate linear regression meth-
ods, with the natural log-transformed form of sST2 as the dependent 
variable. The effect of each determinant was derived from exponen-
tiated regression coefficients.27 Statistical analyses on patients were 
completed using R 2.13.3, including the MASS library.
Results
p75NTR Impairs Postischemic Angiogenesis, 
BF Recovery, and Closure of Ischemic 
Wounds in Diabetic Mice
When limb ischemia and calf wounds were induced at 1 
month of DM, no differences among either p75KO and WT 
mice or DM and non-DM were observed in postischemic 
foot BF recovery or in wound closure (Figure IA and IB 
in the online-only Data Supplement), which may depend 
on a longer time required for DM to induce vascular 
liabilities in c57BL/6J mice. In line with this hypothesis, 
after 3 months of DM, in WT mice, the foot BF recovery 
was impaired in comparison with age-matched nondiabetic 
controls (P<0.05; Figure 1A). Importantly, p75KO mice 
were protected from DM-induced depressed BF recovery. 
Moreover, at 14 days postischemia capillary and small 
arteriole (≤50 μm in diameter) densities in adductor 
(Figure 1B and 1D) and gastrocnemious (Figure 1C and 
1E) muscles were lower in diabetic WT mice (P<0.05 for 
all comparisons versus nondiabetic WT mice). Noteworthy, 
capillary and arteriolar densities were normal in diabetic 
p75KO mice (P=NS for all comparisons versus both 
nondiabetic WT mice and nondiabetic p75KO mice). As 
shown in Figure 2A and 2B, in the absence of DM, the 
ischemic wounds closed similarly in both p75KO and 
WT mice. DM compromised the initial phase (3 days) 
of wound healing in WT mice, which confirms what we 
previously published using an interscapular wound healing 
model.23 By contrast, p75KO mice were protected from 
DM-induced impairment of wound closure (P<0.05 versus 
diabetic WT mice). Granulation tissue is a vascularized 
connective tissue that typically grows from the base of a 
wound to fill it. One of the critical factors for a successful 
wound healing is the rapid establishment of a perfused 
granulation tissue.28 DM in combination with ischemia 
reportedly impairs the development and maturation of 
the granulation tissue.29 Here, we assayed the granulation 
tissue of 3-day wounds for thickness, vascularity, and EC 
apoptosis. The granulation tissue thickness was similar 
in nondiabetic WT and p75KO and WT mice (500±30 μm 
versus 482±40; P=0.562). In WT mice, granulation tissue 
thickness was reduced by DM (162±13 μm; P<0.01 versus 
non-DM), which simultaneously compromised wound 
reepithelization. p75NTR knockout partially preserves skin 
granulation tissue integrity in diabetic mice. In fact, the 
p75KO diabetic wounds showed a thicker granulation 
tissue (247±25 μm; P<0.001 versus DM in WT) and were 
completely epithelized. Moreover, as shown in Figure 2C, 
DM reduced wound vascular density in WT mice (P<0.05 
versus non-DM), whereas p75KO mice were protected 
(P=NS and P<0.05 versus nondiabetic WT and diabetic 
WT mice, respectively). Furthermore, as shown in Figure 
2D, DM increased EC apoptosis in ischemic wounds of WT 
mice (P<0.05 versus DM) but not in p75KO mice (P=NS 
versus both nondiabetic WT and p75KO mice and P<0.05 
versus diabetic WT mice).
Taken together, the above data suggest that p75NTR contrib-
utes in the delayed healing of ischemic wounds of diabetic 
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mice by impairing the development of the granulation tissue, 
reducing wound angiogenesis and increasing EC apoptosis.
Effects of Diabetes Mellitus and p75NTR on 
the Mouse Transcriptomic Profile in Ischemic 
Skin Wounds and Adductor Muscles
We have previously identified a set of angiogenesis-related 
genes (VEGF-A, ITGB1, VEZF1, BIRC5, and PTTG1), which 
are repressed by p75NTR overexpression in HUVECs.5 In 
adductor muscles of WT mice, DM decreased the VEGF-A, 
BIRC5, and PTTG1 mRNA levels, which conversely were 
elevated in p75KO muscles (Figure II in the online-only Data 
Supplement). In skin wounds of WT mice, DM downregu-
lated the mRNA expression of VEGF-A, BIRC5, and VEZF1, 
whereas p75KO diabetic mice maintained a normal (similar to 
nondiabetic WT mice) expression for these genes (Figure III 
in the online-only Data Supplement).
Next, to identify the whole profile molecular changes 
associated with the differential responses to DM by p75KO 
mice, parts of the wounds harvested at 3 days were dedicated 
to mRNA expressional analyses using Agilent 4x44k arrays. 
Transcriptome analysis (GEO accession number, GSE34675) 
identified a set of 40 genes differentially expressed in the 
ischemic wounds of diabetic versus nondiabetic WT mice 
and whose expression in DM was normalized by p75NTR 
knockout (Table II in the online-only Data Supplement 
and Figure IVA in the online-only Data Supplement). 
These genes were clustered for their functional annotation 
using GeneCodis 2.030 (Figure IVB in the online-only 
Data Supplement). This analysis identified that cytokine–
cytokine receptor interaction pathway, cell adhesion 
molecules, tight junction genes, and leukocyte–EC 
interaction pathways were mainly affected by DM and 
p75NTR. Among the genes identified accordingly to the 
Figure 1. p75 neurotrophin receptor (p75NTR) 
knockout normalizes postischemic neovascu-
larization and blood flow recovery in 3-month 
diabetic mice. A, Unilateral limb ischemia was 
performed in 3-month diabetic (Diab) and non-
diabetic (non diab) wild-type (WT) and p75KO 
mice. Representative color laser Doppler 
images of limb blood flow (BF) taken at 3 days 
postischemia are shown. Line graph shows 
the time course of postischemic foot BF 
recovery (calculated as the ratio between isch-
emic and contralater foot BF; n=12 mice per 
group). B and C, Column graphs show capil-
lary density in ischemic (14 days postsurgery) 
adductor (B) and gastrocnemious (C) muscles 
(n=6 per group). D and E, Column graphs 
show small arterioles (diameter <50 mm) den-
sities in ischemic adductors (D) and gastroc-
nemous (E) muscles (n=6 per group). *P<0.05 
vs diabetic WT mice; #P<0.05 vs nondiabetic 
WT mice. Data represent mean±SEM.
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Figure 2. Accelerated wound closure in diabetic 
p75KO mice. A, Healing of a 5-mm-diameter cuta-
neous wound was monitored using digital photog-
raphy in diabetic (Diab) and nondiabetic (non diab) 
wild-type (WT) and p75KO mice with limb ischemia. 
Representative photos are shown. B, Wound size 
is reported as percentage of the initial wound area. 
*P<0.05 vs diabetic WT mice; #P<0.05 vs nondia-
betic WT mice. Data represent mean±SEM (n=12). 
C, Capillary density in the granulation tissue was 
quantified after CD31 staining (red fluorescence).  
D, Apoptosis in endothelial cells (ECs) in granulation 
tissue was evaluated by costaining with terminal 
deoxynucleotidyl transferase dUTP nick end label-
ing (pink merging fluorescence) and CD31 (green 
fluorescence). Nuclei were counterstained with 
4',6-diamidino-2-phenylindole (blue fluorescence). 
Arrows indicate TUNEL-positive EC nuclei. Magni-
fication, ×40. Scale bar, 100 μm *P<0.05 vs diabetic 
WT mice; #P<0.05 vs nondiabetic WT mice. Data 
represent mean±SEM (n=6). KO indicates knockout.
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aforementioned defined criteria, 6 genes (il-1rl1/st2, sfrp1, 
clu, hpc, tnc, and Krt20) were further investigated by 
quantitative RT-PCR (Figure IVC in the online-only Data 
Supplement). Next, we decided to focus on ST2 because this 
receptor is known to be expressed by ECs16 and involved in 
angiogenesis14 and cardiovascular disease.12 The ST2 gene 
produces different sST2 and ST2L mRNA isoforms in both 
humans and mice.9 As shown in Figure 3A, both sST2 and 
ST2L were upregulated at mRNA level by DM in ischemic 
wounds of WT mice (P<0.05 for both comparisons versus 
non-DM). This DM effect was absent in ischemic wounds 
of p75KO mice (P=NS versus nondiabetic p75KO and 
P<0.05 versus diabetic WT mice). IL-33 mRNA expression 
showed an inverted pattern of expression in comparison 
with ST2. ST2L and IL-33 protein expression followed 
that of mRNA expression (Figure 3B). For ST2 analyzes, 
we used a polyclonal antibody that recog nize human and 
mouse ST2L, giving a band of ≈ 63 kDa in the mouse wound 
samples. This antibody did not recognize sST2 in Western 
blot of mouse skin samples.
Similarly to WT wounds, both sST2 and ST2L mRNA were 
upregulated by DM in adductors of WT, but not p75KO mice 
(Figure VA in the online-only Data Supplement). Moreover, 
IL-33 mRNA expression in skin was downregulated by 
DM in WT mice, only (Figure VA in the online-only Data 
Supplement).
Localization of ST2 in Vascular Cells in Mouse 
Adductor Muscles and Skin Wounds
Ischemic dermal wounds and adductor muscles of diabetic WT 
mice were submitted to immunohistochemical analyses. In 
mouse adductor muscles, ST2 is expressed in smooth muscle 
cells of arterioles (positive for α-smooth muscle actin; Figure 
VB in the online-only Data Supplement), but not in capillary 
ECs (positive for isolectin-B4, Supplementary Figure VC) 
and it appears additionally expressed by myocytes (Figure VB 
and VC in the online-only Data Supplement). In mouse skin 
wounds, ST2 is expressed by microvascular ECs and colocal-
izes with p75NTR (Figure 3C). These data allow speculating 
for a possible expressional regulation of the ST2 by p75NTR in 
vascular cells.
p75NTR Regulates ST2 Expression in Cultured ECs
It was previously shown that impairment of wound heal-
ing in diabetic skin correlates with TNF-α expression31 and 
that TNF-α increases the secretion of sST2 from ECs.32 
Moreover, TNF-α was shown to promote p75NTR expression 
in astrocytes.33 Phorbol-12-myristate-13-acetateate is known 
to increase the expression of both ST2 forms in ECs32 and 
hence can be used as a positive control. We found that 16 
hours incubation with either TNF-α or phorbol-12-myristate-
13-acetateate upregulated both p75NTR and ST2 protein lev-
els in HUVECs, whereas IL-33 was downregulated (Figure 
4A). In HUVECs, the used ST2 antibody detected 2 different 
bands at 62 kDa and 50 kDa, which probably identify ST2L 
and sST2, respectively.34 Western blot analysis on HUVEC 
conditioned culture medium confirmed the 50-kDa band as 
released and hence nonmembrane-bound ST2 form (data not 
shown). Moreover, sST2 concentration in the HUVEC con-
ditioned culture medium was increased by either TNF-α or 
phorbol-12-myristate-13-acetateate (Figure 4B). Next, the 
participation of p75NTR in ST2 upregulation was demonstrated 
using a RNA silencing approach. HUVECs were transfected 
with oligos for specifically silencing p75NTR and then treated 
with TNF-α for 16 hours. p75NTR silencing prevented the TNF-
α–induced expression of ST2L and sST2 (Figure 4C). In the 
same experimental setting, the level of sST2 in the HUVEC 
conditioned culture medium was reduced by p75NTR silencing 
(Figure 4D). To determine a possible mechanism of regula-
tion of both ST2 isoforms by p75NTR, we first investigated 
the signaling cascade activated in HUVECs in response to 
p75NTR overexpression achieved by adenovirus (Ad)-mediated 
human p75NTR transfer. One hallmark in p75NTR signaling in 
neural cells is the activation of the c-Jun N-terminal kinase 
pathway.35 However, we did not observe changes in c-Jun 
N-terminal kinase phosphorylation (Thr183/Tyr185) in ECs 
transduced with p75NTR (Figure 4E). By contrast, overexpres-
sion of the p75NTR for 24 hours induced the phosphorylation 
(Thr180/Tyr182) of p38MAPK and ATF-2 (Thr69/71), a 
p38MAPK target (Figure 4E). Phosphorylation of p38MAPK 
and ATF-2 have been previously demonstrated important for 
ATF-2 transcriptional activity.36 Importantly, the increase of 
ST2L and sST2 expression after p75NTR overexpression was 
prevented by ATF-2 silencing (Figure 4F and 4G). Moreover, 
p75NTR overexpression in HUVECs increased c-Jun protein 
level, and this response was inhibited by ATF-2 knockdown 
(Figure 4F). Finally, c-Jun silencing further demonstrated that 
this transcription factor is also required for p75NTR-modulated 
increase in sST2 and ST2L (Figure 4H and 4G).
Expression of the IL-33/ST2 System in Limb 
Ulcers and Serum of Patients With CLI and DM
To investigate whether our findings in mice and cultured 
ECs could have a potential clinical relevance, we examined 
the expression of p75NTR, ST2, and IL-33 in skin samples 
obtained from major limb amputation of diabetic CLI patients 
(patients are described in the Table). As shown in Figure 
VI in the online Data Supplement, p75NTR was expressed in 
small arteries of the adventitia (red arrow), in venules (yellow 
arrows), and in microvessels (white arrow). Similarly, ST2 
was expressed in venules (yellow arrows) and in microvessels 
(white arrows). IL-33 localization was predominantly in the 
nuclei of EC (green arrows) belonging to blood vessels of dif-
ferent calibres, as previously reported for other organs also in 
nondiabetic subjects.37
Next, we measured serum levels of sST2 and IL-33 
in 4 group of subjects (see the Table): nondiabetic and 
nonischemic patients undergoing vena saphena stripping 
(controls, n=11); nondiabetic patients with CLI undergoing 
revascularization to attempt limb salvage (n=8); diabetics 
patients with CLI undergoing revascularization (n=53); and 
diabetic patients with CLI undergoing major limb amputation 
(n=14). As shown in Figure 5A, in nondiabetic CLI patients 
undergoing revascularization, sST2 levels were comparable 
with controls (153.4±62.6 pg/mL versus 142.8±41.2 
pg/mL; P=NS). By contrast, serum sST2 levels were higher 
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Figure 3. ST2/interleukin-33 (IL-33) characterization in skin wounds. A, Relative expression of ST2L, sST2, and IL-33 in skin wounds of 
diabetic and nondiabetic wild-type (WT) and p75KO mice. Results were normalized to 18S expression. Data represent mean±SEM, n=5. 
*P<0.05 vs diabetic WT mice; #P<0.05 vs nondiabetic WT mice; §P<0.05 vs nondiabetic p75KO mice. B, Representative Western blot 
analyses of ST2L and IL-33 in skin wounds of diabetic and nondiabetic WT and p75KO mice. Bar graphs show relative protein quantifica-
tion of ST2L and IL-33. Relative values are normalized by α/β Tubulin levels. Western blot data represent means± SD, n=3. *P<0.05 vs 
diabetic WT mice; #P<0.05 vs nondiabetic WT mice. C, Fluorescent immonocytochemistry for ST2 (green fluorescence), p75 neurotrophin 
receptor (p75NTR; red fluorescence), and CD31 (blue fluorescence) in skin wounds of diabetic WT mice. Magnfication, ×63. Scale bar,  
50 μm.
in diabetic CLI patients undergoing revascularization 
(271.8±138.7 pg/mL; P<0.05 versus healthy) and further 
increased in even more compromised diabetic CLI patients, 
who necessitated major limb amputation (552.5±118.7 
pg/mL; P<0.05 versus any other group). We could not detect 
IL-33 in the serum of our patients and control subjects. As 
shown in Figure VII in the online-only Data Supplement, 
circulating level of TNF-α increased in serum of diabetic 
patients undergoing revascularization, only (37.7±9.3 
pg/mL versus 10±4.2 pg/mL in healthy controls; P<0.05). 
Circulating VEGF-A, sTie-2, and thrombospondin-1 levels 
were found elevated in patients with severe peripheral artery 
disease and their expression to correlate with the severity of 
the disease.38,39 In addition, serum levels of placental growth 
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Figure 4. p75 neurotrophin receptor (p75NTR) regulates 
the expression of ST2. A, Representative Western blot 
bands for p75NTR, ST2, and interleukin (IL)-33 proteins  
of human umbilical vein endothelial cells (HUVECs) 
treated with treated for 16 hours with either tumor 
necrosis factor-α (TNF-α) at the concentration of  
10 ng/mL or phorbol-12-myristate-13-acetateate (PMA) 
at the concentration of 1 μmol/L for 16 hours (data are 
quantified in Supplementary Figure 9A). B, Detection of 
sST2 by ELISA assay in the medium of HUVECs treated 
as reported above. *P<0.05 vs dimethyl sulfoxide 
(DMSO); #P<0.05 vs PBS. C, HUVECs were transfected 
with small interfering RNA (siRNA) oligos for p75NTR or 
control oligos and treated with TNF-α for 16 hours. 
Representative Western blot bands for p75NTR and ST2 
(data are quantified in Figure IXB in the online-only Data 
Supplement). D, Detection of sST2 by ELISA assay 
in the medium of HUVECs after p75NTR silencing and 
TNF-α treatment. ELISA data represent mean±SEM, 
*P<0.05 vs control; #P<0.05 vs control+TNF-α. (n=3). 
E, Representative Western blot analyses for p75NTR, 
phospho–c-Jun N-terminal kinase (p-JNK), JNK, 
phospho−mitogen-activated protein kinase (p-p38MAPK), 
p38MAPK, phospho–activating transcription factor 2 
(p-ATF-2), ATF-2, and ST2 proteins of HUVECs cells 
infected with adenovirus (Ad).Null or Ad.p75NTR (data are 
quantified in Figure XIE in the online-only Data Supple-
ment). F, Representative Western blot bands for ATF-2, 
c-Jun, and ST2 proteins of HUVECs transfected with 
ATF-2 siRNA oligos and subsequently infected with 
Ad.Null or Ad.p75NTR (data are quantified in Figure XIF 
in the online-only Data Supplement). G, Representa-
tive Western blot bands for c-Jun and ST2 proteins of 
HUVECs cells transfected with c-Jun siRNA oligos and 
subsequently infected with Ad.Null or Ad.p75NTR (data 
are quantified in Figure XIG in the online-only Data  
Supplement). H, Detection of sST2 by ELISA assay 
in the medium of HUVECs after ATF-2, c-Jun silenc-
ing, p75NTR or null transduction. ELISA data represent 
mean±SEM. *P<0.05 vs Ad.Null+control; #P<0.05 vs 
control+Ad.p75NTR (n=3).
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factor are reportedly elevated in patients with ischemic 
cardiomyopathy.40 We measured these 4 factors in our patient 
populations. As shown in Figure VII in the online-only Data 
Supplement, VEGF-A, sTie-2, and thrombospondin-1 were 
similarly elevated in the 3 groups of CLI, whereas placental 
growth factor was increased in diabetic patients with CLI 
undergoing major limb amputation only.
Serum sST2 Level Correlates With 
Mortality in Diabetic CLI Patients 
Undergoing Revascularization
Next, limited to the 53 diabetic patients undergoing revas-
cularization to treat CLI, we investigated whether circulat-
ing sST2 level could be statistically associated with baseline 
clinical variables (Table) or clinical outcomes (Table I in the 
online-only Data Supplement) at 1-year follow-up from revas-
cularization. Because of the moderate sample size, in our anal-
ysis we avoided the use of nonlinear modeling approaches, 
such as generalized (GLM) or additive (GAM) regression 
models, because these typically require a larger amount of 
data to provide efficient and reliable estimates. We rather used 
a data transformation in association with a linear regression 
model. We had evidence of substantial Gaussianization effect, 
and therefore we adopted the logST2 as response variable in a 
linear regression model. Most baseline clinical characteristics, 
including sex, age, DM-related pathologies, hemoglobin A1c 
level, and extent of coronary artery disease, did not correlate 
with baseline sST2 level. Furthermore, at least in our data set, 
there is no evidence for a significant effect of VEGF-A, Tie-2, 
placental growth factor, and thrombospondin-1 on log ST2. 
The continuous variable TNF-α has a nonsignificant effect, in 
agreement with data published by Shimpo et al21 in acute MI. 
By contrast and importantly, both indicator variables for anti-
glycemic medications and for death of patients during 1-year 
follow-up have a significant effect on sST2 (Table III in the 
online-only Data Supplement). In particular, the antiglycemic 
medication had a strong effect in reducing the level of sST2 
(Figure VIII in the online-only Data Supplement), whereas the 
death within 1-year follow-up was directly related to increased 
levels of sST2 (Figure 5B).
Finally, it has been demonstrated that there is a significant 
negative correlation between circulating levels of sST2 and 
platelets counts in dengue-infected patients.41 We did not find 
any significant difference in the level of sST2 between plasma 
and serum in healthy volunteer (plasma, 148±12 pg/mL; 
serum, 153±22 pg/mL; P=0.777; n=5). In our patients, no sig-
nificant correlation between platelet counts and level of circu-
lating ST2 (r=−0.0773; P=0.953) and nonsignificant effect on 
the variable sST2 have been detected (Table III in the online-
only Data Supplement). Moreover, indicator variables for anti-
platelet drugs (acetyl salicylic acid, clopidogrel, ticlopidine, 
and dicumarolic anticoagulants) have nonsignificant effect on 
sST2 (Table III in the online-only Data Supplement).
Taken together, these data provide the first evidence that 
sST2 measured immediately before revascularization of isch-
emic limb predicts mortality at 1-year follow-up and that the 
level of circulating sST2 inversely correlates with the use of 
antiglycemic medications.
Discussion
Diabetic patients exhibit an insufficient capacity in the heal-
ing of acute wounds, which often develop into chronic ulcers 
in their feet and lower limbs. The impaired wound healing 
response in diabetic subjects involves multiple and complex 
pathophysiological mechanisms, including defective angio-
genesis. We already provided evidences that DM induces 
p75NTR expression in ECs of intra-scapular skin wounds7 and 
ischemic limb muscles.6 We also demonstrated that p75NTR 
impairs EC survival and functions and that its expression is 
responsible for DM-induced defective postischemic angio-
genesis in limb muscles.5
Here, we report for the first time that p75NTR gene dele-
tion accelerates the healing of ischemic skin wound in the 
lower limbs of diabetic mice. To better mimic human dia-
betic ulcers, a full excisional skin wound was created in the 
calf area of diabetic mice after induction of ipsilateral limb 
ischemia. In this model, which was recently established by 
us23 and already validated by others,29 the presence of mus-
cular ischemia further delays wound healing. Importantly, 
when subjected to this model, diabetic p75KO mice exhibited 
accelerate wound closure, improved reparative angiogenesis, 
and reduced EC apoptosis in granulation tissue in comparisons 
Figure 5. Serum soluble ST2 (sST2) levels in critical limb isch-
emia patients. A, Serum sST2 level in nondiabetic nonischemic 
patients (controls, n=11), nondiabetic patients with critical limb 
ischemia (CLI) undergoing revascularization to attempt limb 
salvage (n=8), diabetic patients with CLI undergoing revascular-
ization (n=53), and diabetic patients with CLI undergoing limb 
amputation (n=14). ELISA data represent mean±SEM. *P<0.05 
and **P<0.01 vs controls; #P<0.05 and ##P<0.01 vs nondiabetic 
CLI patients undergoing revascularization; §P<0.05 vs diabetic 
CLI patients undergoing revascularization. B, Dot plot shows the 
baseline concentrations of sST2 in patients experiencing death 
and the survivor group (at 1-year follow-up).
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with diabetic WT mice. Moreover, in diabetic p75KO mice, 
both postischemic muscular angiogenesis and foot BF recov-
ery were better than in diabetic WT mice, thus confirming 
the results that we previous obtained after local Ad-mediated 
transfer of a p75NTR dominant negative mutant form to inhibit 
receptor activity in diabetic WT mice with limb ischemia.5
To profile the molecular changes associated with p75NTR 
and DM in ischemic wounds, we used a RNA microarray. 
Transcriptome analysis identified a set of genes differen-
tially expressed in diabetic versus nondiabetic WT mice and 
whose expression was normalized by p75NTR knockout. These 
genes were clustered for their functional annotation, showing 
enrichment for genes involved in cytokine–receptor interac-
tion pathway, cell adhesion molecules, tight junction genes, 
and leukocytes transendothelial migration pathways. We 
noted that components of these pathways were upregulated 
by DM in the presence of the p75NTR only. We decided to 
focus on ST2 to further develop our study. ST2 was already 
known to be expressed by ECs16 and involved in inflamma-
tory angiogenesis.14 In skin, ST2 is expressed in ECs and 
keratinocytes. However, ST2 role in ischemic complication 
of DM was unknown, as well as the mechanisms of induction 
of ST2 expression in diabetic wound healing. ST2 expression 
in ECs is known to be modulated by proinflammatory cyto-
kines, including TNF-α.32 Moreover, type 2 DM is associ-
ated with high serum levels of TNF-α and high local TNF-α 
levels have been identified as a molecular predictive factor 
for nonhealing ulcers.42 In this study, we found circulating 
TNF-α to be increased in patients with DM and CLI requir-
ing revascularization, but not in diabetic CLI patients requir-
ing amputation. Notwithstanding, TNF-α supplementation 
proved a good model to induce p75NTR and ST2 expression in 
cultured ECs and helped define the importance of p75NTR for 
ST2 expression in ECs. In fact, p75NTR silencing prevented 
ST2 expression in TNF-α–stimulated ECs. Importantly, in 
vivo, p75NTR and ST2 colocalize in dermal EC of diabetic 
murine wounds, which reinforces the possibility of a depen-
dence of ST2 from p75NTR. Next, we went more insight the 
mechanisms mediating ST2 regulation by p75NTR. In ECs, 
the p38MAPK pathway is activated by stress-inducing stimuli, 
including reactive oxygen species, hyperglycemia, and pro-
inflammatory cytokines, such as TNF-α.43 Here, we have 
identified that increased p75NTR levels induce the phosphor-
ylation of p38MAPK and ATF-2 in HUVECs, whereas c-Jun 
N-terminal kinase pathway is not involved. Moreover, using 
a gene silencing approach, we have demonstrated that ATF-2 
and c-Jun are regulated by p75NTR and are both necessary for 
ST2 transcription. The ST2 proximal promoter is predomi-
nantly responsible for both ST2 isoforms expression in ECs,16 
and it is mainly regulated by activator protein 1 transcrip-
tion factor complex.44 Whereas ATF-2 forms homodimers 
that bind CRE-like recognition sequences, the heterodimers 
with other activator protein 1 family members, such as c-Jun, 
allow for binding to typical activator protein 1 sequences in 
gene promoters.36 In addition, the ATF-2 direct transcrip-
tional regulation of c-Jun is activated by stress-inducing 
stimuli in a wide number of cell lines.45 In response to p75NTR 
stimulation, cells induce both the upregulation of c-Jun and 
the activation of ATF-2, which could possibly bind together 
to ST2 proximal promoter and converge in the activation of 
its transcription.
sST2 has been recently proposed as a novel diagnostic 
biomarker for cardiovascular disease, including acute MI 
and heart failure.19,20,27,46 Moreover, Sabatine et al showed 
highly significant increase in circulating sST2 in post-MI 
patients with DM. We have measured sST2 in the serum of 
diabetic patients with CLI requiring either revascularization 
for attempting limb salvage or amputation as only relief from 
unbearable pain and terminal gangrene. Circulating sST2 lev-
els were higher in diabetic CLI patients undergoing revascu-
larization in comparison with either nondiabetic CLI patients 
or healthy subjects. Serum sST2 further increased in diabetic 
patients at the moment of lower limb amputation. Importantly, 
in our patient cohorts, sST2 was not associated with the extent 
of coronary artery disease, thus excluding the possibility that 
our findings in CLI simply reflects the fact that sST2 is bio-
marker of heart disease.19,20
For the 53 diabetic CLI patients undergoing revasculariza-
tion, the clinical follow-up at 1 year was available, allowing 
investigation of the value of sST2 as a predictor of clinical 
outcome. Using a statistical linear regression model, in this 
patient population, sST2 was directly associated with mortal-
ity within 1 year of follow-up.
A handful of studies had previously suggested the capac-
ity of circulating sST2 to predict mortality, both in cardio-
vascular and noncardiovascular patients.21,22 The reasons by 
which sST2 could associate with mortality are still unex-
plored. A limit of our study is that the cause of death for 
some of the patients enrolled in our study was not recorded. 
A prospective study using a larger diabetic CLI patient pop-
ulation is necessary to shed light on the mechanisms under-
pinning the link of sST2 and death. Moreover, it would be 
important to understand whether the mechanisms by which 
sST2 can predict death in diabetic CLI patients are dif-
ferent or similar to those by which sST2 predicts mortal-
ity in other cardiovascular and noncardiovascular patient 
populations.21 An additional limitation of this study is that 
it is based on a relatively small sample size (n=53), and it 
was neither designed nor powered for analysis of effects of 
sST2 on mortality or its interaction with other variables; 
therefore, these results should be considered as hypothesis-
generating only. We would tend to discard the possibility 
that increased sST2 further compromises ulcer healing, 
because in a pilot experiment, we did not record any nega-
tive responses to topical application of sST2 on cutaneous 
ischemic wounds, which closed normally (Meloni, unpub-
lished data, 2011).
In our clinical study, IL-33 could not be detected in the 
serum of any of the studied groups. Whereas circulating 
IL-33 is elevated in inflammatory diseases such as rheumatoid 
arthritis,47 levels of IL-33 freely circulating in the blood of 
cardiovascular patients are likely to be low, possibly because 
of the elevated sST2 levels.
In conclusion, our data identified and describe, for the first 
time, a link between p75NTR and ST2 and propose sST2 as pos-
sible diagnostic and prognostic biomarker in diabetic patients 
with CLI. Further studies are necessary to validate the bio-
marker value of sST2.
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 Supplemental Material 
Human Patients – Ethical issues 
Human studies complied with the ethical principles stated in the “Declaration of Helsinki”.  
Human specimens were obtained from patients participating to two studies conducted under 
the approval of the Ethical Committee of the IRCCS Multimedica, Milan, Italy (IRCCS-
Multimedica number: I) 11/2009 and II) 020/2008). In addition, NHS NRES 11SW/0093 
approval was obtained for human sample import, storage, and analysis at the University of 
Bristol, Bristol, UK. Both are pilot observational studies with the objective of defining cellular 
and molecular targets of diabetic CLI by analyzing tissue samples from surgical leftovers and 
peripheral blood samples. The access to this sample collection allowed us to conduct a 
retrospective analysis of parameters of interest. 
Briefly, study I) 11/2009 was designed to dissect the effect of diabetes on the expression of 
molecular targets to design new targeted therapies for the cure of ischemic diabetic ulcers in 
patients with chronic limb ischemia (CLI). After obtainment of informed written consent, a 
consecutive series of patients was recruited. Two groups were studied: 1) non-diabetic and 
non-ischemic patients undergoing vena saphena stripping (controls, n=10); 2) diabetic 
patients with CLI undergoing major limb amputation (n=14). This study provided limb 
amputation samples for IHC and peripheral blood for serum analysis. 
Study II) 020/2008 aims to determine the mechanisms responsible for vascular progenitor 
cell dysfunction in the perspective of new therapies for the cure of the diabetic foot 
(ClinicalTrials.gov: NCT01269580, Title: Diabetic Foot and Vascular Progenitor Cells). 
Events analyzed at the follow up time, 12 month after percutaneous angioplasty (PTA) 
procedure was performed, are: cardiovascular mortality for all causes, major amputation, 
and post-angioplasty restenosis in treated limb. Two groups of patients with CLI undergoing 
PTA procedure were analyzed: 2) non-diabetic patients with CLI (n=8); 3) diabetics patients 
with CLI (n=53). This study provided peripheral blood samples for serum analysis and follow 
up data for clinical-laboratory data correlation. CLI was defined according to TASC criteria 
(2007): pain at rest, and/or ulcer or gangrene due to artheropaty: transcutaneous oximetry < 
30 mmHg or pressure on the ankle < 70 mmHg.  Exclusion criteria were drug-induced 
diabetes, liver failure or dialysis due to renal failure, cancer with adverse prognosis in 
months, or chemotherapic treatment, pregnancy, lack of consent to participate to the study.  
Animal procedures 
All procedures complied with the standards stated in the Guide for the Care and Use of 
Laboratory Animals (Institute of Laboratory Animal Resources, National Academy of 
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Sciences, Bethesda, MD, USA, 1996) and approved by the UK Home Office.  C57BL/6J-
p75NTR-/- (p75KO) 1 and p75NTR+/+ (WT) littermates were bred at the University of Bristol 
starting from breeding pairs kindly provided by Prof. Beth Habecker, Oregon Health and 
Science University.  Seven to eight  weeks old male p75KO and WT mice were made 
diabetic using streptozotocin (Sigma) (STZ, 40 mg/kg in 0.1mol/l citrate buffer pH4.5 i.p. per 
day for 5 days)2 or left normoglycemic by STZ buffer injections. For the STZ groups, 
persistence of glycosuria ≥10 g/L was checked over the duration of the experiments. One or 
three months after diabetes induction, anesthetized (Avertin, 880 mmol/kg, i.p., Sigma) mice 
underwent induction of unilateral hindlimb ischemia by permanent ligation and electro-
coagulation of the proximal end of left femoral arteries. At the same time, a full thickness 
wound was created in the thigh dorsal skin of the ischemic legs using a sterile 5-mm-wide 
biopsy punch3. After surgery, animals were maintained in cages with food and water ad 
libitum and in a temperature and humidity-controlled environment. Laser Doppler perfusion 
image analysis (Perimed) was performed at baseline to confirm limb ischemia and at 3, 7 
and 14 days thereafter to monitor BF recovery4. Clinical outcome was established by 
determining the rate of wound closure3. To this aim, two perpendicular diameters of the 
wound were measured by using a Vernier caliper and wound area was calculated using a 
standard formula for the area of an ellipse (semi-major diameter X semi-minor diameter X 
Pi). Wound area was evaluated immediately after punching and then at 3, 7 and 14 days 
afterwards.  Mice were sacrificed at either 3 or 14 days post-surgery. At 3 days, mice were 
sacrificed by an overdose of anaesthetic and the wounds and surrounding skin were 
removed and perpendicularly cut into two halves. One half was immediately frozen for 
molecular biology studies while the other was fixed in 4% buffered formalin solution and 
further processed for histology or immunohistochemical analyses.  At 14d post-surgery, the 
limbs of terminally anaesthetised mice were perfusion/fixed and ischaemic adductor muscles 
harvested and processed for paraffin embedding. 
RNA extraction, microarray and quantitative RT-PCR on mouse samples 
RNA was extracted from wounds using the FastPrep tissue lyser (MPbio) and RNeasy 
AllPrep kits (Qiagen). Twelve single channel hybridisations (using Cy3-dye) on Agilent 4x44k 
arrays were analysed. Gene ontology (GO analysis) enrichment analysis was carried out 
using GeneCodis 2.05 (www.http://genecodis.dacya.ucm.es). Array data were registered in 
GEO (accession number: GSE34675). Quantitative RT-PCR (Q-PCR) sfrp1 (Secreted 
frizzled-related protein 1), Hpx (Hemopexin), clu (Clusterin), tnc (Tenascin), krt20 (Keratin 
20), vegfa (vascular endothelial growth factor A), vezf1 (vascular endothelial zinc finger 1), 
itgb1 (integrin beta-1), birc5 (survivin), pttg1 (securin) and il-33 and for the housekeeping 
hprt1(hypoxanthine phosphoribosyltransferase 1) and rpl13a (60S ribosomal protein L13a) 
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or 18s (18s ribosomal RNA) was performed using validated primers  (Applied Biosystems). 
For murine il1rl1 (ST2, sequence shared by both isoforms) primer sequences are: sST2 
forward 5’-CTTGTTCTCCCCGCAGTC-3’, reverse 5’- CCAATGTCCCTTGTAGTCGG-3’ 
probe 5’-TCCCCATCTCCTCACCTCCCTTAAT 3’; mouse ST2L forward 5’-
TCTGTGGAGTACTTTCACC-3’ reverse 5’-TCTGCTATTCTGGATACTGCTTTC-3’ probe 5’-
AGAGACCTGTTACCTGGGCAAGATG-3’. Data normalisation was performed by geometric 
averaging.6  
 
Immunhistochemistry on human and murine tissues  
Sections of tissue (5 m) were deparaffinized in xylene and rehydrated. Slides were 
incubated in a solution of 0.5% hydrogen peroxidase in methanol followed by antigen 
retrieval in 0.5 M citrate buffer (pH 6) and incubation in 2.5% horse serum (Vector 
Laboratories). Sections were stained overnight with rabbit anti-mouse ST2 (Abnova), rabbit 
anti-human ST2 (Sigma), rabbit anti-mouse p75NTR (Abcam), rat anti-mouse CD31 (BD 
Biosciences) or appropriate IgG control (Dako), followed by incubation with ImmPRESS 
reagent horse anti-mouse Ig or anti-rabbit Ig (Vector Laboratories).  Signal was developed 
using the peroxidase substrate DAB (Vector Laboratories). Harris’s haematoxylin (BDH) was 
used for counterstaining. For fluorescent immunohistochemistry, secondary antibodies were 
goat anti-rabbit or goat anti-mouse conjugated to Alexa-488 or Alexa-568 fluorophores 
(Molecular Probes). 
Microvascular density in wounds was counted after staining for CD31. Apoptosis of ECs was 
assessed by in situ TUNEL assay combined with CD31 staining. Muscular capillary and 
arteriole densities were measured in transverse section (5µm thickness) of the ischemic 
adductor and gastrocnemius muscles after staining with fluorescent isolectin-B4 (EC marker; 
1:100, Invitrogen) and with an antibody for α-smooth muscle actin (α-SMA, 1:400, for 
marking vascular smooth muscle cells, Sigma). Fifteen fields (20X magnification) were 
randomly examined and averaged to analyze number of capillaries, while number of small 
arterioles (diameter ≤ 50μm) were analysed considering whole muscle area. Capillary and 
arteriole density is expressed per square millimetre. 
 
Statistical Analyses 
Group differences of continuous variables were compared by one-way ANOVA or Student t 
test, as appropriate. Continuous data are expressed as mean ± SEM. A P value <0.05 was 
considered statistically significant.  
For statistical analysis of microarray experiments, all exploratory data analysis and all data 
pre-processing were performed in R / Bioconductor. Data preprocessing included the 
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following steps: background correction using Agilent spatial detrending background estimate, 
averaging of replicate spots, log2-transformation, KNN imputation of missing values, 
unsupervised filtering (IQR threshold) to get rid of uninformative probes (low variance), 
Quantile Normalisation. For inference statistics, the linear modelling functions provided by 
the Limma package were used. Determinants of the prognostic value of circulating sST2 
levels were assessed using multivariate linear regression methods, with the natural log-
transformed form of sST2 as the dependent variable. The effect of each determinant was 
derived from exponentiated regression coefficients 7. Statistical analyses on patients were 
completed using R 2.13.3, including the MASS library. 
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Supplementary Table I: Clinical outcome at one-year follow up for the 53 diabetic patients 
undergoing revascularization for critical limb ischemia 
Patients Diabetics with CLI undergoing Revascularization 
(n=53) 
Restenosis 29/53 RES 
Amputation 7/53 AMP 
Death 6/53 D 
 
AMP=amputation, RES=restenosis, D=death 




Supplementary Table II: List of 40 genes which are differentially expressed in the ischemic 
wounds of diabetic wild type (WT) mice vs, non-diabetic WT mice and whose expression in 
diabetes was normalised by p75NTR gene knock-out (p75KO).  
Gene Symbol Gene name 
logFC WT no diab 
vs WT diab 
logFC WT diab vs 
p75KO diab 
Lhx8 LIM homeobox protein 8 -3.987 -3.828 
Hpx Hemopexin -1.122 -1.861 
Krt20 keratin 20 -0.656 -1.598 
Trh thyrotropin releasing hormone -1.248 -1.340 
Pnet-ps 
prenatal ethanol induced 
mRNA, pseudogene -1.008 -1.292 
Clu Clusterin -0.868 -1.195 
Syt13 synaptotagmin XIII -0.886 -1.155 
Penk Preproenkephalin -1.553 -1.082 
Il1rl1 interleukin 1 receptor-like 1 -1.468 -1.074 
Fam148b 
family with sequence similarity 
148, member B -0.913 -1.065 
Tmem56 transmembrane protein 56 -0.611 -1.018 
Cbln1 cerebellin 1 precursor protein -1.355 -0.899 
Pot1b protection of telomeres 1B -0.812 -0.894 
Abcd3 
ATP-binding cassette, sub-
family D (ALD), 3 -1.147 -0.845 
Pogz 
pogo transposable element with 
ZNF domain -0.964 -0.799 
Stc1 stanniocalcin 1 -1.039 -0.798 
Tnc tenascin C -1.375 -0.790 
Olfr351 olfactory receptor 351 -0.924 -0.727 
Fam167a 
family with sequence similarity 
167, member A -0.701 -0.701 
Mc5r melanocortin 5 receptor -0.776 -0.699 
Igk-V38 
immunoglobulin kappa chain 
-0.793 -0.670 











family with sequence similarity 
55, member C -0.950 -0.604 
Tinagl1 
tubulointerstitial nephritis 
antigen-like 1 -0.684 -0.581 
Oosp1 oocyte secreted protein 1 0.531 0.595 
Olfr836 olfactory receptor 836 0.847 0.614 
Ropn1l ropporin 1-like 0.581 0.681 
D1Pas1 
DNA segment, Chr 1, Pasteur 
Institute 1 1.073 0.735 
Frem2 
Fras1 related extracellular 
matrix protein 2 0.665 0.752 
Tmie transmembrane inner ear 0.671 0.756 
Hormad1 HORMA domain containing 1 0.651 0.784 
Gm2824 predicted gene 2824 0.656 0.805 
Gm5087 predicted gene 5087 0.979 0.819 
Serpina1f 
serine (or cysteine) peptidase 
inhibitor,  1F 0.855 0.871 
Dpys Dihydropyrimidinase 0.902 0.914 
Prkce protein kinase C, epsilon 0.892 0.920 
Creg2 
cellular repressor of E1A-
stimulated genes 2 0.714 0.929 
Ly9 lymphocyte antigen 9 0.924 1.106 
Usp11 ubiquitin specific peptidase 11 1.710 1.204 
F7 coagulation factor VII 1.410 1.539 
Arl5c ADP-ribosylation factor-like 5C 0.742 1.569 






Supplementary Table III: Correlation between sST2 and other variables in 53 diabetic 
patients with critical limb ischemia undergoing surgical revascularization 
Coefficient 
Effect on ST2  
(%) 
Est. coef. on 
log(ST2) Std. Error t value Pr(>|t|) 
(Intercept) -- 4.671 0.261 17.904 0 
Anti-glycemic drugs 
at baseline -56.2 -0.5620 0.22 -2.547 0.015 
Death by 12 months 59.9 0.599 0.263 2.271 0.028 
Platelet count 
at the baseline 0.1 0.001 0.0007 0.0739 0.941 
Anti-platelet agents 
at baseline -31.1 -0.3116      0.1832   -1.701    0.097 
 
    . 
 
 




Supplementary Figure I: Blood flow recovery and wound healing in mice with one 
months of diabetes. A, Unilateral limb ischemia was performed in diabetic (Diab) and non-
diabetic (non Diab) wild-type (WT) and p75NTR-knockout (p75KO) mice after 1 months of 
diabetes.  Line graph shows the time-course of post-ischemic foot blood flow (BF) recovery 
(calculated as the ratio between ischaemic and contra-later foot BF). B, Healing of a 5-mm–
diameter cutaneous wound was monitored using digital photography in WT and p75KO 
diabetic (Diab) and nondiabetic (Non Diab) mice after 1 month of diabetes with hind limb 
ischemia. Wound size is reported as percentage of the initial wound area. Data represent 
means ± SEM. 
 




Supplementary Figure II:  Modulation of p75NTR-regulated genes in adductor muscles 
by diabetes in WT and p75KO mice Expression levels of selected genes (vegfa, birc5, 
itgb1, vezf1, pttg1) in skin wounds were determined using Q-PCR.  Results were normalized 
to 18S expression. Q-PCR data represent means ± SEM (n=5). #p<0.05 vs. non-diabetic WT 
mice; *p<0.05 vs. diabetic WT mice.  




Supplementary Figure III:  Modulation of p75NTR-regulated genes in skin wounds by 
diabetes in WT and p75KO mice .  Expression levels of selected genes (vegfa, birc5, itgb1, 
vezf1, pttg1) in adductor muscles were determined using Q-PCR.  Results were normalized 
to 18S expression. Q-PCR data represent means ± SEM (n=5). #p<0.05 vs. non-diabetic WT 
mice; *p<0.05 vs. diabetic WT mice.  
 








Supplementary Figure IV:  Modulation of gene profile in skin wounds by diabetes in 
WT and p75KO mice.  A, Heatmap of differentially expressed genes in the ischemic 
wounds of diabetic WT mice vs WT non diabetic mice and whose expression was 
normalized in diabetic p75KO mice.  B, Gene ontology annotation analysis using Genecodis 
2.0.  C, Validation of microarray expression analysis.  Expression levels of selected genes 
(IL1RL1 (ST2), sFRP1 Hpx, CLU, Tnc, Krt20) were independently determined using Q-PCR.  
Results were normalized to HPRT and RPL13a expression. Q-PCR data represent means ± 
SEM (n=3). #p<0.05 vs. non-diabetic WT mice; *p<0.05 vs.. diabetic WT mice.  




Supplementary Figure V:  IL-33 and ST2 expression in adductor muscles. A, Relative 
mRNA expression of ST2L, sST2 and IL-33 in adductor muscles of diabetic and non-diabetic 
WT and p75KO mice. Results are normalized to 18S expression. Data represent means ± 
SEM, n = 5 *p<0.05 vs. diabetic WT mice; #p<0.05 vs. non-diabetic WT mice. §p<0.05 vs 
non diabetic p75KO mice. B, Fluorescent immonocytochemistry for ST2 (green 
fluorescence), and -SMA(red fluorescence) in ischemic adductor muscles of diabetic WT 
mice. Nuclei were counterstained with DAPI (blue fluorescence). C, Fluorescent 
immonocytochemistry for ST2 (green fluorescence), and isolectin–B4 (red fluorescence) in 
ischemic adductor muscles of diabetic WT mice. Nuclei were counterstained with DAPI (blue 
fluorescence). Magnfication: 100x. Scale bar, 10μm 






Supplementary Figure VI: Detection and localization of p75NTR, ST2 and IL-33 in the 
human skin from amputated ischemic legs of diabetic patients.  p75NTR, ST2 and IL-33 
are expressed in human skin. Human skin biopsies from amputated diabetic patients were 
paraffin processed and immunostained for isotype control (panel a), p75NTR (panel b), ST2 
(panel c) and IL-33 (panel d). Representative histology of n=5 patients is shown. 
Magnification 40×; scale bars: 5 μm. Venules: yellow arrows; Small arteries: red arrows; 











Supplementary Figure VII: Circulating levels of TNF- VEGF-A, soluble Tie-2, TSP-1, 
and PIGF in patients with critical limb ischemia and controls. Serum levels of TNF- 
VEGF-A, soluble Tie-2, TSP-1 and PIGF in non-diabetic non-ischemic controls (n=11), non-
diabetic patients critical limb ischemia (CLI) undergoing revascularization (n=8), diabetics 
patients with CLI undergoing revascularization (n=53), and diabetic patients with CLI 
undergoing limb amputation. (n=14). ELISA data represent means ± SEM. *p<0.05 vs 
controls. 




Supplementary Figure VIII: Correlation between sST2 and use of antiglycemic drugs. 
Dot plot showing the baseline concentrations of sST2 in diabetic patients with CLI 
undergoing revascularization and treated (black circle) or not (black bars) with anti-glycemic 
drugs.  
 




















Supplementary Figure IX: Densitometry quantification of western blot analyses shown 
in Figure 4; A, Bar graphs show relative protein quantification of p75NTR, sST2, ST2L and 
IL-33. Relative values are normalized by  Tubulin levels. *p<0.05 vs. DMSO (vehicle 
PMA); #p<0.05 vs. PBS (vehicle TNF-B, Bar graphs show relative protein quantification 
of p75NTR , sST2 and ST2L.  Relative values are normalized by 
vs. control; #p<0.05 vs control+TNF-. E, Bar graph show relative protein quantification of 
p75NTR, p-38MAPK, p-JNK, p-ATF-2, sST2 and ST2L.  Relative values are normalized by 
Tubulin levels or total protein. *p<0.05 vs. Ad.Null;  F, Bar graph show relative protein 
quantification of ATF-2, c-Jun, sST2 and ST2L.  Relative values are normalized by 
Tubulin levels. *p<0.05 vs. Ad.Null+control; #p<0.05 vs Ad.p75+control; G, Bar graph 
show relative protein quantification of c-Jun, sST2 and ST2L.  Relative values are 
normalized by Tubulin levels. *p<0.05 vs. Ad.Null+control; #p<0.05 vs. Ad.p75+control 
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